Perjeta (pertuzumab) / Roche 
Welcome,         Profile    Billing    Logout  
 80 Diseases   208 Trials   208 Trials   5617 News 


«12...4647484950515253545556...7172»
  • ||||||||||  Review, Journal:  HER2-targeted therapies - a role beyond breast cancer. (Pubmed Central) -  Apr 23, 2020   
    The experience with gastric cancer suggests that the successes observed in HER2-positive breast cancer might not be replicated in these other tumour types, owing to differences in the level of HER2 overexpression and other aspects of disease biology. In this Review, we describe the current role of HER2-targeted therapies beyond breast cancer and also highlight the potential of novel HER2-targeted agents that are currently in clinical development.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Clinical, Journal:  Stage Ⅳ Breast Cancer with Difficulty in Initiating Chemotherapy-A Case Report (Pubmed Central) -  Apr 23, 2020   
    First, she underwent chemotherapy with trastuzumab and capecitabine...Subsequently, trastuzumab, pertuzumab, and docetaxel were administered, as liver function became normal...Finally, she underwent mastectomy. Five years after the first visit, she has continued chemotherapy, with lung metastases almost scarred(CR).
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Journal:  Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer. (Pubmed Central) -  Apr 17, 2020   
    Finally, in heregulin-expressing BT474-HRG and JIMT-1 xenograft models, the addition of pertuzumab and patritumab to trastuzumab also enhanced antitumor efficacy leading to tumor regression. The current study found that triple blockade of HER2 and HER3 using trastuzumab, pertuzumab, and patritumab could overcome resistance to trastuzumab therapy in heregulin-expressing and HER2-positive breast cancer, which could be exploited clinically.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    [VIRTUAL] Loss of HER2 after neoadjuvant treatment of HER2+ early breast cancer (ePosters) -  Apr 17, 2020 - Abstract #ESMOBCI2020ESMO_BC_I_406;    
    Initial treatment with trastuzumab and pertuzumab conditions a greater loss of HER2 expression (50%) and especially in cases with initial HER2 +2 with 70% with total loss of expression. We will need to find some new treatment strategy for this group of patients with loss of HER2 expression, especially if they have a low expression of HER2 in the initial diagnosis.Legal entity responsible for the study: The authors.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    [VIRTUAL] Loss of HER2 after neoadjuvant treatment of HER2+ early breast cancer (ePosters) -  Apr 17, 2020 - Abstract #ESMOBCI2020ESMO_BC_I_241;    
    Initial treatment with trastuzumab and pertuzumab conditions a greater loss of HER2 expression (50%) and especially in cases with initial HER2 +2 with 70% with total loss of expression. We will need to find some new treatment strategy for this group of patients with loss of HER2 expression, especially if they have a low expression of HER2 in the initial diagnosis.Legal entity responsible for the study: The authors.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Preclinical, Journal, Combination therapy:  In vitro cytotoxic effect of Trastuzumab in combination with Pertuzumab in breast cancer cells is improved by interleukin-2 activated NK cells. (Pubmed Central) -  Apr 16, 2020   
    In this study, we explored the cytotoxic effect of recombinant human IL-2 in combination with Trastuzumab and Pertuzumab on the ERBB2 positive (SK-BR-3) and negative (MDA-MB-231) breast cancer cell lines. The cytotoxicity level of IL-2 activated NK cells (approximately 75%) were significantly higher than untreated cells (approximately 55%) in the presence of Trastuzumab and Pertuzumab against SK-BR-3 cells, while no difference was observed in the case of MDA-MB-231 cells (about 15%).
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Clinical, Journal:  A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action. (Pubmed Central) -  Apr 14, 2020   
    Combination of three antibodies, 19H6-Hu, inetetamab (a trastuzumab analog) and pertuzumab exhibited much stronger inhibition of large NCI-N87 tumor xenografts (>400mm) than the current standard of care, inetetamab (trastuzumab) plus Docetaxel (DTX), as well as the combination of 19H6-Hu, inetetamab and DTX. Our results highlight the functional variability of HER2 domains and provide a new insight into the design of HER2-targeting agents.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Clinical, Review, Journal:  The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer. (Pubmed Central) -  Apr 11, 2020   
    The results reported in the published clinical trials demonstrated a higher pathologic complete response rate in breast and lymph nodes after using targeted therapy with two anti-Her-2/neu agents - Trastuzumab and Pertuzumab in combination with neoadjuvant chemotherapy for early-stage Her-2/neu positive breast cancers. The pathologic complete response rate is the most important prognostic marker in Her-2/neu positive tumors, a higher pathologic complete response rate being demonstrated to be associated with a better survival outcome in terms of higher overall survival and disease-free survival rates.
  • ||||||||||  Perjeta (pertuzumab) / Roche, docetaxel / Generic mfg.
    Journal:  Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar. (Pubmed Central) -  Apr 10, 2020   
    Continued follow-up is warranted to evaluate long-term outcomes. Overall, the equivalence of SB3 with reference product in MoA-related qualities in in vitro mono- and combination therapy experiments may support clinical bioequivalence of the two substances.
  • ||||||||||  Perjeta (pertuzumab) / Roche
    Enrollment closed, Trial completion date, Trial primary completion date:  CARE-B: CARdiac Function Evaluation in Breast Cancer Patients (clinicaltrials.gov) -  Apr 2, 2020   
    P=N/A,  N=25, Active, not recruiting, 
    Recruiting --> Suspended Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2020 | Trial primary completion date: Dec 2022 --> Feb 2020
  • ||||||||||  paclitaxel / Generic mfg., Herzuma (trastuzumab biosimilar) / Nippon Kayaku, Pfizer, Mundipharma, Celltrion, Teva
    Journal:  Mechanism of action of the trastuzumab biosimilar CT-P6. (Pubmed Central) -  Apr 1, 2020   
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2020 | Trial primary completion date: Dec 2022 --> Feb 2020 Collectively, the results of this study show that the mechanisms of action of CT-P6 and trastuzumab are similar in HER2-positive breast cancer and gastric cancer models and, therefore, CT-P6 can be expected to perform similarly in the clinical setting.